The implantable drug delivery devices market is expected to witness robust growth due to the recent developments taking place in genomics, proteomics and biotechnology that have led to emerging classes of novel pharmaceutical compounds across the globe that helps to accelerate the market. Furthermore, an increase in the burden of chronic diseases is affecting the large patient population which increases the number of surgeries and hence drives the implantable drug delivery devices market. According to the World Health Organization (WHO) 2017, chronic diseases are the major cause of disabilities worldwide. The estimated global burden by 2020 would be 60% and moreover, 73% of deaths in 2020 is expected due to chronic diseases. However, the high cost of devices and surgery costs, low rate of adoption are the few restraining factors of the growth of implantable drug delivery devices market.

Key Market Trends

Infusion pumps segment holds significant market share

Infusion pumps are devices that are used to deliver fluids into a patient’s body, in a controlled manner. They are capable of supplying medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Infusion pumps play an important role in delivering accurate medications in chemotherapy, for diabetics, etc., for the corresponding diseases. The rising number of diabetes cases and increasing investments in diabetes care and management have helped in the adoption of insulin infusion pumps. Technological advancements, coupled with increasing R&D initiatives on gastrointestinal disorders, cancer, neurological problems, and AIDS, are providing lucrative opportunities for infusion pumps in the market. According to the FDA, in 2017, Baxter’s Sigma Spectrum Infusion pump has been the number one infusion pump in drug library compliance. Sigma Spectrum has a user interface that provides top-quality patient safety margins and has the ability to integrate with leading electronic medical record systems.

North America Dominates the Implantable Drug Delivery Devices Market

In North America, the medical device industry is a highly regulated sector of the economy. There are several studies that suggest that the US manufacturers of implantable devices can maintain high prices, in part due to structural barriers such as costly regulatory approval processes and patent protections. Therefore, manufacturers face problems in launching new products in the United States. Hospitals are the primary purchasers of most high-cost implantable devices in the United States, but they have limited bargaining power to negotiate for lower prices. There are millions of Americans being implanted with implantable devices such as artificial hips or cardiac pacemakers, in their bodies. Experts have also estimated that 7.2 million Americans are living with joint implants. However, due to the aging population and the increasing prevalence of chronic conditions, the number of patients adopting implantable devices continues to grow exponentially. During the past year, in the United States, there have been many advancements in technology and medical innovation, which have expanded the types of implantable devices, to include artificial hearts and deep-brain stimulators to control epilepsy.

Competitive Landscape

Market players are focusing on new product launches, minimizing the price of the tests in order to gain maximum traction in the global market. Furthermore, market players are concentrating on various growth strategies such as collaborations, acquisitions, partnerships to enhance their market presence. For instance, Jan 2018: Medtronic Plc has received FDA approval of a new clinician programmer for use with the SynchroMed(TM) II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. Major market players are Boston Scientific Corporation, Bausch and Lomb Inc., Delpor Inc., Medtronic, pSivida Corp. and Teleflex Incorporated among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client’s requirements
  • 3 months of analyst support